In 2015, the FDA approved the combination of vemurafenib and the MEK inhibitor cobimetinib for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.113. The gene discussed is MAP2K7; the disease is metastatic melanoma.